This internship is for Summer 2021
Machine learning lies at the core of insitro’s approach to rethinking drug development. As a small molecule machine learning intern, you will lead the development of cutting edge machine learning methods that solve key problems in the drug development process. You will work closely with a cross-functional team of life scientists, bioengineers, and data scientists to identify areas where machine learning can make a difference, to conceptualize and develop chemical datasets using cutting edge high throughput platforms, to prototype and build robust data processing pipelines, and to analyze these datasets using the best machine learning methods, applied at scale. You will need to come up with novel methods that use a broad spectrum of machine learning approaches, including cutting edge techniques. You will work as part of a team to rigorously analyze our data, pull out key insights, and make accurate predictions that will let us quickly develop highly efficacious non-toxic drugs for diseases with urgent unmet needs. . You will work closely with a very talented team, learn a broad range of skills, receive close mentoring from senior scientists and engineers, and help shape insitro’s culture, strategic direction, and outcomes. Join us, and help make a difference to patients!
Nice to Have
Benefits at insitro
insitro is a data-driven drug discovery and development company using machine learning and high-throughput biology to transform the way that drugs are discovered and delivered to patients. The company is applying state-of-the-art technologies from bioengineering to create massive data sets that enable the power of modern machine learning methods to be brought to bear on key bottlenecks in pharmaceutical R&D. The resulting predictive models are used to accelerate target selection, to design and develop effective therapeutics, and to inform clinical strategy. insitro was launched in 2018 with a Series A of $100M funded by top investors including a16z, Arch Venture Partners, Foresite Capital, GV, and Third Rock Ventures. In 2019 the company announced a collaboration with Gilead Sciences in the area of NASH and, in mid 2020, announced a Series B financing of $143M including current investors and new investors Canada Pension Plan Investment Board (CPP Investments), T. Rowe Price, BlackRock, Casdin Capital and other leading investors. The company is located in South San Francisco, CA. For more information about insitro, please visit the company’s website at www.insitro.com.
Your application was submitted successfully.